Report cover image

Dyslipidemia by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2032

Publisher GlobalData
Published Jul 28, 2023
Length 144 Pages
SKU # GBDT18132702

Description

Dyslipidemia by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2032


Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the dyslipidemia market through 2032.

Examples of key findings from this report include the following -
  • 2022 base year sales within the dyslipidemia market are approximately $5.6 billion across the 7MM detailed in this report. GlobalData estimates that this market will grow at a compound annual growth rate (CAGR) of 10.8% to reach $15.5 billion by the end of the forecast period.
  • The growth of the PCSK9 class, among others in the dyslipidemia pipeline, highlights the current expansion of biologics into the dyslipidemia market. However, due to their high prices, there is a significant disconnect between patients who are eligible for treatment based on regulatory approval and those who receive treatment. In response to this, there is ample opportunity for more cost-effective therapies targeting the more general dyslipidemia market. This is where pipeline drugs such as Merck’s first oral PCSK9 inhibitor, MK-0616, will address this unmet need.
Key Highlights

According to GlobalData, the drug sales in the dyslipidemia market are expected to grow significantly between 2022 and 2032, with an overall compound annual growth rate (CAGR) of 10.8%. In 2022, GlobalData estimated the total dyslipidemia market to be valued at $5.56 billion across the 7MM. In 2022, the US made up the majority of total global sales, with $4.12 billion (74%). The 5EU accounted for 21% of the global dyslipidemia market sales with an estimated value of $1.18 billion million and Japan’s dyslipidemia market sales were estimated to be $252.9 million in 2022, accounting for 5% of the market.

By the end of the forecast period in 2032, GlobalData expects the dyslipidemia market to grow at a CAGR of 10.8%, reaching sales of $15.53 billion, with the US accounting for 78% of the global market with a market value of $12.06 billion. This could be due to the large prevalence of dyslipidemia in the US, as well as the higher overall price of drugs as compared to the 5EU and Japan. Moreover, the US has more pipeline drugs entering the dyslipidemia market during the forecast period compared to the 5EU and Japan. The 5EU is anticipated to grow with a CAGR of 8.3%, reaching sales of $2.63 billion. Japan accounts for 5% of the total sales with a CAGR of 12.8% by the end of the forecast period.

Major drivers of the dyslipidemia market growth during the forecast period are -
  • The increasing global prevalence of dyslipidemia due to an increase in obesity, sedentary lifestyles, and unhealthy dietary habits. As the global population continues to age, the prevalence of dyslipidemia is likely to increase.
  • Improved awareness about the health risks associated with dyslipidemia and increased efforts in screening and diagnosis are expected to lead to more people being diagnosed with the condition.
  • Therapies with new targets will enter the market, which will significantly boost market growth.
  • The launch of the first oral PCSK9 inhibitor, Merck’s MK-0616, as well as other promising pipeline therapies, including NewAmsterdam’s oral CETP inhibitor, obicetrapib, and Akcea Therapeutics’s apoC-III, olezarsen.
    • Major barriers that will restrict the growth of the dyslipidemia market during the forecast period are:
  • The price of novel launched drugs for dyslipidemia and the restriction of access to highly priced new therapies.
  • Widespread use of cheap, generic drugs making it difficult for high-priced branded therapies to penetrate the market.
  • Continued generic erosion of Pfizer’s Lipitor, AstraZeneca’s Crestor (rosuvastatin), as well as Merck’s Zetia (ezetimibe) across the 7MM.
Scope
  • Overview of dyslipidemia, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized dyslipidemia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the dyslipidemia therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for dyslipidemia treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM dyslipidemia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM dyslipidemia therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Please note: this is delivered as an Excel file.

Table of Contents

144 Pages
1 Dyslipidemia: Executive Summary
1.1 Dyslipidemia market will exhibit strong growth during the forecast period, reaching sales of $15.53 billion in 2032
1.2 Key players will continue their competitive position in the dyslipidemia market over the forecast period
1.3 Patient compliance, the availability of cost-effective drugs, and therapies that target lipoprotein (a) are the greatest unmet needs in the dyslipidemia space
1.4 Late-stage pipeline therapies are anticipated to drive growth in the dyslipidemia market
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.5 Epidemiological forecast for dyslipidemia (2022–32)
4.6 Discussion
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Therapies that target lipoprotein (a)
7.3 Efficacious triglyceride-lowering therapies
7.4 Cost-effective therapies for dyslipidemia
7.5 Personalized treatment
7.6 Improving diagnosis, patient education, and long-term compliance
8 R&D Strategies
8.1 Overview
8.2 Clinical trials design
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research – KOLs interviewed for this report
13.5 Primary research – prescriber survey
13.6 About the authors
Contact Us
List of Tables
Table 1: Dyslipidemia: key metrics in the 7MM
Table 2: Fredrickson’s classification of dyslipidemia
Table 3: Risk factors and comorbidities for dyslipidemia
Table 4: Total prevalent cases of increased LDL-C, both sexes, N, ages ≥20 years, 2022–32
Table 5: Total prevalent cases of high TGs, both sexes, N, ages ≥20 years, 2022–32
Table 6: Total prevalent cases of very high TGs, both sexes, N, ages ≥20 years, 2022–32
Table 7: Total prevalent cases of low HDL-C, both sexes, N, ages ≥20 years, 2022–32
Table 8: AACE optimal/near-optimal, borderline, and high-risk serum lipid concentrations
Table 9: Factors considered for different CVD risk calculators
Table 10: Treatment guidelines for dyslipidemia
Table 11: Top 10 deals by value, 2018–22
Table 12: Dyslipidemia market – global drivers and barriers, 2022–32
Table 13: Key events impacting sales for dyslipidemia in the US, 2022–32
Table 14: Dyslipidemia market – drivers and barriers in the US, 2022–32
Table 15: Key events impacting sales for dyslipidemia in the 5EU, 2022–32
Table 16: Dyslipidemia market – drivers and barriers in the 5EU, 2022–32
Table 17: Key events impacting sales for dyslipidemia in Japan, 2022–32
Table 18: Dyslipidemia market – drivers and barriers in Japan, 2022–32
Table 19: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for dyslipidemia in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in dyslipidemia during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of dyslipidemia during the forecast period
Figure 4: Modern classification of dyslipidemia, and primary and secondary causes
Figure 5: Target of marketed and pipeline therapies
Figure 6: 7MM, total prevalence of dyslipidemia, men and women, %, ages ≥20 years, 2022
Figure 7: 7MM, diagnosed prevalence of dyslipidemia, men and women, %, ages ≥20 years, 2022
Figure 8: 7MM, sources used and not used to forecast the diagnosed prevalent cases of dyslipidemia
Figure 9: 7MM, sources used and not used to forecast the total prevalent cases of high LDL-C
Figure 10: 7MM, sources used and not used to forecast the total prevalent cases of high TGs and very high TGs
Figure 11: 7MM, sources used and not used to forecast the total prevalent cases of low HDL-C
Figure 12: 7MM, sources used and not used to forecast the total prevalent cases of FH
Figure 13: 7MM, sources used to forecast the total prevalent cases of mixed dyslipidemia
Figure 14: 7MM, total prevalent cases of dyslipidemia, N, both sexes, ages ≥20 years, 2022
Figure 15: 7MM, total prevalent cases of dyslipidemia by age, N, both sexes, 2022
Figure 16: 7MM, total prevalent cases of dyslipidemia by sex, N, ages ≥20 years, 2022
Figure 17: 7MM, diagnosed prevalent cases of dyslipidemia, N, both sexes, ages ≥20 years, 2022
Figure 18: 7MM, diagnosed prevalent cases of dyslipidemia by age, N, both sexes, 2022
Figure 19: 7MM, diagnosed prevalent cases of dyslipidemia by sex, N, ages ≥20 years, 2022
Figure 20: 7MM, total prevalent cases of FH, N, both sexes, ages ≥20 years, 2022
Figure 21: 7MM, total prevalent cases of increased LDL-C by age, N, both sexes, 2022
Figure 22: 7MM, total prevalent cases of increased LDL-C by sex, N, ages ≥20 years, 2022
Figure 23: 7MM, total prevalent cases of high TGs by age, N, both sexes, 2022
Figure 24: 7MM, total prevalent cases of high TGs by sex, N, ages ≥20 years, 2022
Figure 25: 7MM, total prevalent cases of very high TGs by age, N, both sexes, 2022
Figure 26: 7MM, total prevalent cases of very high TGs by sex, N, ages ≥20 years, 2022
Figure 27: 7MM, total prevalent cases of low HDL-C by age, N, both sexes, 2022
Figure 28: 7MM, total prevalent cases of low HDL-C by sex, N, ages ≥20 years, 2022
Figure 29: 7MM, total prevalent cases of mixed dyslipidemia, N, both sexes, ages ≥20 years, 2022
Figure 30: AHA/ACC and ESC/EAS guidelines
Figure 31: Unmet needs and opportunities in dyslipidemia
Figure 32: Overview of the development pipeline in dyslipidemia
Figure 33: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for dyslipidemia in the 7MM during the forecast period
Figure 34: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for dyslipidemia in the 7MM during the forecast period
Figure 35: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care (SOC), statins
Figure 36: Analysis of the company portfolio gap in dyslipidemia during the forecast period
Figure 37: Global (7MM) sales forecast by country for dyslipidemia in 2022 and 2032
Figure 38: Global (7MM) sales forecast by drug class for dyslipidemia in 2022 and 2032
Figure 39: Sales forecast by drug class for dyslipidemia in the US in 2022 and 2032
Figure 40: Sales forecast by drug class for dyslipidemia in the 5EU in 2022 and 2032
Figure 41: Sales forecast by drug class for dyslipidemia in Japan in 2022 and 2032

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us